Balchem (NASDAQ:BCPC) Stock Rating Lowered by Wall Street Zen

Wall Street Zen lowered shares of Balchem (NASDAQ:BCPC) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning.

Several other research firms also recently weighed in on BCPC. Sidoti upgraded Balchem to a “hold” rating in a research note on Tuesday, February 25th. HC Wainwright set a $180.00 target price on Balchem and gave the company a “buy” rating in a research note on Monday, April 28th.

Balchem Stock Down 0.9%

BCPC stock opened at $165.96 on Wednesday. Balchem has a fifty-two week low of $145.70 and a fifty-two week high of $186.03. The business’s 50 day moving average price is $161.80 and its two-hundred day moving average price is $166.27. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.16 and a current ratio of 1.99. The company has a market capitalization of $5.41 billion, a price-to-earnings ratio of 42.23, a price-to-earnings-growth ratio of 4.41 and a beta of 0.93.

Balchem (NASDAQ:BCPC) last posted its quarterly earnings results on Thursday, April 24th. The basic materials company reported $1.22 earnings per share for the quarter, missing the consensus estimate of $1.25 by ($0.03). The company had revenue of $250.52 million during the quarter, compared to analysts’ expectations of $245.70 million. Balchem had a return on equity of 11.37% and a net margin of 13.47%. The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.03 EPS. As a group, analysts forecast that Balchem will post 4.64 earnings per share for the current fiscal year.

Institutional Trading of Balchem

Several institutional investors have recently added to or reduced their stakes in the business. Compound Planning Inc. boosted its stake in Balchem by 4.1% during the 1st quarter. Compound Planning Inc. now owns 1,789 shares of the basic materials company’s stock valued at $297,000 after purchasing an additional 70 shares during the last quarter. Quadrant Capital Group LLC boosted its stake in Balchem by 8.2% during the 4th quarter. Quadrant Capital Group LLC now owns 989 shares of the basic materials company’s stock valued at $161,000 after purchasing an additional 75 shares during the last quarter. Covestor Ltd boosted its stake in shares of Balchem by 93.8% in the 4th quarter. Covestor Ltd now owns 157 shares of the basic materials company’s stock worth $26,000 after buying an additional 76 shares during the last quarter. Arizona State Retirement System boosted its stake in shares of Balchem by 0.8% in the 4th quarter. Arizona State Retirement System now owns 9,413 shares of the basic materials company’s stock worth $1,534,000 after buying an additional 77 shares during the last quarter. Finally, Vident Advisory LLC boosted its stake in shares of Balchem by 6.0% in the 4th quarter. Vident Advisory LLC now owns 1,421 shares of the basic materials company’s stock worth $232,000 after buying an additional 80 shares during the last quarter. 87.91% of the stock is currently owned by hedge funds and other institutional investors.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.